Arcutis Biotherapeutics, Inc. ARQT
26.20 USD +0.65 (+2.54%)
At closeNov 9, 2026, 4:00 PM EST
26.50 +0.30 +1.13%
After hours · Nov 9, 4:00 PM ET
25.23 Day range 26.43
19.30 52-week range 34.80
- YTD
- -9.78%
- 1 year
- +8.13%
News
defenseworld.net Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an…
benzinga.com TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.- benzinga.com Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first…
globenewswire.com Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
seekingalpha.com Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director…
marketbeat.com Arcutis Biotherapeutics Q3 Earnings Call Highlights Arcutis Biotherapeutics NASDAQ: ARQT raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased…
zacks.com Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year…
benzinga.com Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering ARCUTIS BIOTHERAPEUTICS, INC.$200,000,000Common StockWe have entered into an amended and restated sales agreement, or the Sales Agreement, with TD Cowen, relating to shares of our common stock…
benzinga.com Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript Arcutis Biotherapeutics (NASDAQ:ARQT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…- benzinga.com Arcutis Biotherapeutics Q3 EPS $0.06 Misses $0.12 Estimate, Sales $143.919M Beat $142.592M Estimate Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.12 by 50 percent. This is unchanged from the same period last…
globenewswire.com Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026…
benzinga.com Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44 Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
benzinga.com Why Is Arcutis Biotherapeutics Stock Surging Thursday? Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.- benzinga.com Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.